Reply: Is high-dose glucocorticoid beneficial in COVID-19?

Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Elham Farhadi, Ahmadreza Jamshidi, Mahdi Mahmoudi, Abdolrahman Rostamian

Source: Eur Respir J, 57 (4) 2100324; 10.1183/13993003.00324-2021
Journal Issue: April
Disease area: Airway diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Maryam Edalatifard, Maryam Akhtari, Mohammadreza Salehi, Elham Farhadi, Ahmadreza Jamshidi, Mahdi Mahmoudi, Abdolrahman Rostamian. Reply: Is high-dose glucocorticoid beneficial in COVID-19?. Eur Respir J, 57 (4) 2100324; 10.1183/13993003.00324-2021

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Is high-dose glucocorticoid beneficial in COVID-19?
Source: Eur Respir J, 57 (4) 2100065; 10.1183/13993003.00065-2021
Year: 2021

Investigating the steroids and long-acting β2-agonists combination: why do we need more?
Source: Eur Respir J 2004; 23: 501-502
Year: 2004

Pharmacological treatment of severe, therapy-resistant asthma in children: what can we learn from where?
Source: Eur Respir J 2011; 38: 947-958
Year: 2011

Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma
Source: International Congress 2019 – Powerful cohort studies with/without lung function
Year: 2019

Reply: Fixed breathing protocols in multiple-breath-washout testing: truly an option in children?
Source: Eur Respir J, 57 (3) 2100189; 10.1183/13993003.00189-2021
Year: 2021

Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021

Does inhaled corticosteroid use affect the risk of ?COVID-19-related death?
Source: Breathe, 17 (1) 200275; 10.1183/20734735.0275-2020
Year: 2021

Anti-inflammatory therapy COPD: fenspiride and(or) theophylline versus inhaled corticosteroids?
Source: Annual Congress 2007 - Treatment of COPD
Year: 2007

Late Breaking Abstract: Fluticasone/salmeterol combination confers significant benefits in smoking asthmatics
Source: Annual Congress 2010 - Smoking related diseases, damages due to environmental tobacco smoke and smoking control strategies
Year: 2010

Optimising bronchodilator therapy in COPD: Who, why and when?
Source: International Congress 2019 – Personalised medicine in COPD: Matching the patient needs with the right care
Year: 2019

Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021

Inhaled corticosteroids in COPD: friend or foe?
Source: Eur Respir J, 52 (6) 1801219; 10.1183/13993003.01219-2018
Year: 2018

Dehydroepiandrosterone in the treatment of steroid resistant asthma: Whether synthetic nanoform can replace the natural hormone?
Source: Annual Congress 2013 –New drugs in respiratory medicine
Year: 2013

Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?
Source: Eur Respir Rev 2015; 25: 54-64
Year: 2016

Systemic treatment: an adjuvant indication?
Source: Annual Congress 2004 - Lung metastases
Year: 2004

Late Breaking Abstract - What do children, parents and paediatricians feel about the risk of growth suppression of inhaled corticosteroids?
Source: International Congress 2018 – Paediatric asthma: new insights in its prevalence, treatment and treatment failure
Year: 2018

Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021

Oral steroids in asthma: a double-edged sword
Source: Eur Respir J, 54 (5) 1902034; 10.1183/13993003.02034-2019
Year: 2019

LATE-BREAKING ABSTRACT: Inhibition of the ubiquitin-E3-ligase FBXW7 enhances steroid efficacy: New concept for treating steroid insensitivity
Source: International Congress 2015 – Asthma mechanisms and management
Year: 2015

Defining low-dose corticosteroid: the pendulum still oscillates
Source: Eur Respir J 2015; 46: 574-576
Year: 2015